What is US7803839B2 (Exelixis, 2006) in relation to cobimetinib?
US7803839B2 is a U.S. patent assigned to Exelixis that was published in 2010 and claims priority back to a 2006 filing, placing it in the period when Exelixis was building its intellectual-property portfolio around kinase inhibitors and related small-molecule drug candidates. In the context of cobimetinib, patents like this are typically about specific chemical matter (the molecule itself) and/or defined ways of using or making related compounds, rather than about later-stage clinical/regulatory milestones.
The provided information doesn’t include the exact patent title/claims or a specific claim chart mapping this patent to cobimetinib, so I can’t state precisely which claim(s) are implicated by cobimetinib without pulling the patent text and comparing it to cobimetinib’s structure and labeled uses.
How do you check whether US7803839B2 actually covers cobimetinib?
A reliable way to verify coverage is to compare three things from the patent:
- The “claimed compound” scope: whether the claims explicitly cover cobimetinib or a structural sub-group that includes cobimetinib.
- The Markush structure language: whether cobimetinib fits within the claimed variable substituents and linker definitions.
- The use/indication claims: whether cobimetinib’s intended use aligns with the claimed therapeutic method.
If you share the patent title or the key claim number you’re interested in (or paste the relevant claim text), I can help you interpret what the claim language would mean for cobimetinib.
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com is a useful starting point for quickly finding patent records tied to a specific drug, including which patents are listed as relevant and how they relate to exclusivity and litigation. If you want, I can also use it to locate the cobimetinib patent listing that might reference Exelixis patents and then cross-check US7803839B2 against that list.
You can view the resource here: DrugPatentWatch.com
Why this matters for cobimetinib commercialization (generic/biosimilar timing)
If US7803839B2 claims either the cobimetinib active ingredient (composition of matter) or a protected method of use, it can affect when other companies can market a competing product without challenging the patent (for example through invalidity or non-infringement arguments) or waiting for expiry, depending on the exact patent term and any extensions.
The details needed to answer that precisely for US7803839B2 are not included here (e.g., whether it’s still in force, its expiration date, and whether any terminal disclaimers or adjustments apply).
What I need from you to give a precise answer
Send one of the following and I’ll tighten this to a concrete “covers/doesn’t cover” explanation:
- The patent title or the first page link/text for US7803839B2, or
- The specific claim number(s) you care about, or
- A link to where you saw “Exelixis 2006 patent cobimetinib” referenced.
Sources